Good response to cadonilimab as first-line treatment in superaged patient with advanced gastric cancer: a case report.

ABSTRACT

Gastric cancer remains a considerable global health burden, with limited treatment options available for advanced cases, especially for superaged patients. Cadonilimab, a first-in-class bi-specific antibody (BsAb), offer a promising immunotherapy approach by targeting PD-1/CTLA-4 simultaneously. Herein, we present a case report of an 85-year-old patient with HER2-negative advanced gastric cancer who received first-line treatment with cadonilimab combined with chemotherapy, but cadonilimab was discontinued due to the observation of immune-related pneumonitis during treatment. Despite these changes, the patient still exhibited a stable disease condition for a year until now. This case report highlights the potential of cadonilimab in the treatment of superaged patients with advanced gastric cancer, while the efficacy and safety of it need to be further evaluated.

At present, immunotherapy plus chemotherapy is the standard first-line treatment for patients with advanced gastric cancer. However, immunotherapy is generally not used in elderly patients over 75 years of age due to safety concerns and the treatment options for these patients are very limited. In this paper, we report a case of successful treatment of cadonilimab (novel immunotherapy drug) plus chemotherapy in an 85-year-old male patient with advanced gastric cancer. Until now, the survival time of this patient is over 12 months, and the quality of life is satisfactory.